Ultragenyx Pharmaceutical (RARE) Operating Leases (2019 - 2025)
Ultragenyx Pharmaceutical (RARE) posted quarterly Operating Leases of $24.0 million for Q4 2025, down 20.0% year-over-year from $30.0 million in Q4 2024, and up 10.64% quarter-over-quarter from $21.7 million in Q3 2025.
Ultragenyx Pharmaceutical (RARE) Operating Leases (2019 - 2025) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Operating Leases for 7 consecutive years, with $24.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Leases fell 20.0% year-over-year to $24.0 million; the TTM figure through Dec 2025 stood at $24.0 million (down 20.0% YoY), while the FY2025 annual figure was $24.0 million, down 20.0% from the prior year.
- Operating Leases improved to $24.0 million in Q4 2025 per RARE's latest filing, from $21.7 million in the prior quarter.
- Across five years, Operating Leases topped out at $36.8 million in Q1 2021 and bottomed at $14.8 million in Q2 2023.
- Historically, Operating Leases has averaged $26.8 million across 5 years, with a median of $26.8 million in 2022.
- Annual changes were most pronounced in 2023 — Operating Leases sank 42.69% — and 2024, when it jumped 73.4%.
- Ultragenyx Pharmaceutical's Operating Leases stood at $30.9 million in 2021, then sank by 35.89% to $19.8 million in 2022, then jumped by 54.31% to $30.6 million in 2023, then declined by 1.88% to $30.0 million in 2024, then slipped by 20.0% to $24.0 million in 2025.
- Business Quant data shows RARE's Operating Leases at $24.0 million in Q4 2025, $21.7 million in Q3 2025, and $24.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 24.00 Mn |
| Sep 30, 2025 | 21.69 Mn |
| Jun 30, 2025 | 24.53 Mn |
| Mar 31, 2025 | 27.79 Mn |
| Dec 31, 2024 | 30.00 Mn |
| Sep 30, 2024 | 23.66 Mn |
| Jun 30, 2024 | 25.74 Mn |
| Mar 31, 2024 | 27.98 Mn |
| Dec 31, 2023 | 30.57 Mn |
| Sep 30, 2023 | 34.56 Mn |
| Jun 30, 2023 | 14.85 Mn |
| Mar 31, 2023 | 17.34 Mn |
| Dec 31, 2022 | 19.81 Mn |
| Sep 30, 2022 | 22.87 Mn |
| Jun 30, 2022 | 25.90 Mn |
| Mar 31, 2022 | 28.04 Mn |
| Dec 31, 2021 | 30.90 Mn |
| Sep 30, 2021 | 33.34 Mn |
| Jun 30, 2021 | 35.86 Mn |
| Mar 31, 2021 | 36.75 Mn |